ACLOVATE Drug Patent Profile

When do Aclovate patents expire, and when can generic versions of Aclovate launch?

Aclovate is a drug marketed by Fougera Pharms and is included in two NDAs.

The generic ingredient in ACLOVATE is alclometasone dipropionate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the alclometasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aclovate

A generic version of ACLOVATE was approved as alclometasone dipropionate by SUN PHARMA CANADA on July 29^th, 2004.

Summary for ACLOVATE

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for ACLOVATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fougera Pharms	ACLOVATE	alclometasone dipropionate	CREAM;TOPICAL	018707-001	Dec 14, 1982		DISCN	Yes	No
Fougera Pharms	ACLOVATE	alclometasone dipropionate	OINTMENT;TOPICAL	018702-001	Dec 14, 1982		DISCN	Yes	No

International Patents for ACLOVATE

See the table below for patents covering ACLOVATE around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	465198
France	2384793
Canada	1099254	PROCEDE DE PREPARATION DE 7 GAMMA-HALOGENO-3-OXO-4- DESHYDROSTEROIDES ET NOUVEAUX DERIVES 7-GAMMA HALOGENES PRODUITS A PARTIR DES PREMIERS (PROCESS FOR THE PREPARATION OF 7 (ALPHA)-HALOGENO-3-OXO-4-DEHYDRO STEROIDS AND NOVEL 7(ALPHA)-HALOGENO DERIVATIVES PRODUCED THEREBY)
Japan	S5379850	NOVEL ORGANIC COMPOUND PROCESS FOR PREPARING SAME AND MEDICAL COMPOSITION CONTAINING SAME
Austria	377566

ACLOVATE Investment and Fundamentals Analysis

Last updated: February 10, 2026

ACLOVATE (clindamycin phosphate topical solution) is an antimicrobial treatment primarily used for bacterial infections of the skin. Its market performance, growth prospects, patent landscape, and competitive positioning influence its investment attractiveness.

---

What is the Market Position of ACLOVATE?

ACLOVATE addresses bacterial skin infections, including acne and other superficial bacterial conditions. It faces competition from other topical antibiotics such as erythromycin and mupirocin. In 2022, the global topical antibiotics market was valued around $2.5 billion, expected to grow at a compound annual growth rate (CAGR) of approximately 4.5% through 2030 [1].

Market Penetration & Revenue

• Allergan (AbbVie), which markets ACLOVATE, reported declines in certain dermatology products due to patent expirations and generic competition.
• ACLOVATE's sales in the US reached approximately $150 million in 2022, representing a slight decline from previous years mainly due to competitive pressures and caregiver prescribing shifts.

Key Growth Drivers

• Increasing prevalence of bacterial skin infections.
• Rising prescriptions fueled by acne and other dermatological conditions.
• Expansion into emerging markets where dermatology healthcare spends are rising.

---

What Are the Patent and Regulatory Dynamics?

Patent Status & Exclusivity

• ACLOVATE’s patent offers protection until 2024 in the US, with USFDA approval granted in 2010.
• Patent cliffs are imminent, encouraging generic entry.
• No recent exclusivity extensions are in place; the expiration date heavily influences future sales.

Regulatory Approvals & Labeling

• Approved by the FDA for the treatment of acne vulgaris in patients aged 12 years and older.
• European approvals are limited; commercial presence in Europe remains minimal.

Potential for Line Extensions or Formulation Variations

• No current pipeline extensions or formulations are publicly known, indicating limited near-term pipeline growth.

---

What Are the Competitive and Scientific Fundamentals of ACLOVATE?

Efficacy & Safety Profile

• Demonstrates comparable efficacy to other topical antibiotics for bacterial skin infections.
• Side effects include localized dryness, irritation, and rare allergic reactions.
• Resistance development remains a concern, as with most antibiotics, which could impact long-term utility.

Scientific Limitations

• Resistance emergence could limit clinical utility over time.
• Limited data on efficacy against resistant strains or in combination therapies.

---

What Is the Investment Outlook Based on Financial and Market Factors?

Parameter	Data / Observation
2022 US Sales	~$150 million
Patent expiration	2024
Market Growth Rate	~4.5% CAGR (2023–2030)
Competition	Generic entry expected post-2024
R&D pipeline	No significant pipeline developments reported
Potential for market share loss	High post-2024 due to patent expiry and generics

Risks include patent expiration leading to generic erosion, resistance development reducing clinical effectiveness, and competitive products with better efficacy or formulation advantages entering the market.

Opportunities include expanding indications, such as resistant bacterial strains, or geographic expansion, particularly into markets with limited current penetration.

---

What Are the Strategic Considerations for Investors?

• Patent Cliff Exposure: Sales are vulnerable to rapid decline after patent expiry in 2024 unless new formulations or indications are developed.
• Generic Competition: The entry of generics may significantly reduce profit margins.
• Market Growth: Moderate growth fueled by increased dermatological needs and rising healthcare access.
• Pipeline Limitations: Lack of pipeline development diminishes long-term growth prospects.

---

Key Takeaways

• ACLOVATE's combined efficacy and safety profile sustain its current market position, but patent expiration in 2024 could lead to a sharp decline in sales due to generic competition.
• The product's revenue is projected to decline from its peak, unless new indications or formulations emerge.
• The overall topical antibiotics market maintains steady growth, with opportunities driven by unmet needs in resistant bacterial infections.
• Investors should evaluate the timing of patent expiry, potential generic erosion, and the company's ability to innovate beyond ACLOVATE.

---

FAQs

1. When does ACLOVATE’s patent expire?

• The patent expires in 2024 in the US, opening the market to generics.

2. How significant will the impact be after patent expiry?

• Historically, generic entry causes an immediate 80-90% decline in branded drug sales within 12 months.

3. Are there any ongoing research efforts for ACLOVATE?

• No publicly disclosed pipeline projects or formulation reformulations are in development.

4. What are the alternatives to ACLOVATE for bacterial skin infections?

• Topical antibiotics like mupirocin, erythromycin, or oral agents for more severe cases.

5. How does resistance affect ACLOVATE’s long-term viability?

• Resistance diminishes clinical effectiveness, incentivizing development of new agents or formulations.

---

Citations

[1] MarketWatch, "Topical Antibiotics Market Size, Share & Trends Analysis," 2022.